LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, today announced the presentation of positive
results from the Phase II clinical trial of Puma's investigational drug
PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY
2 TRIAL) in an oral presentation at the American Association for Cancer
Research (AACR) Annual Meeting 2014 in San Diego, California. The
presentation entitled “Neratinibmore...